Status:

COMPLETED

A Safety Study Of Pregabalin In Fibromyalgia

Lead Sponsor:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions:

Fibromyalgia

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

To evaluate the safety of pregabalin in patients with fibromyalgia.

Eligibility Criteria

Inclusion

  • Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites.
  • Patients must complete the double-blind study.

Exclusion

  • Patients who experienced a serious adverse event during the previous fibromyalgia study, which was determined to be related to the study medication.

Key Trial Info

Start Date :

February 1 2006

Trial Type :

INTERVENTIONAL

End Date :

October 1 2006

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT00282997

Start Date

February 1 2006

End Date

October 1 2006

Last Update

January 22 2021

Active Locations (72)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 18 (72 locations)

1

Pfizer Investigational Site

Little Rock, Arkansas, United States

2

Pfizer Investigational Site

Fresno, California, United States

3

Pfizer Investigational Site

La Jolla, California, United States

4

Pfizer Investigational Site

Northridge, California, United States